Overview

An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY

Status:
Active, not recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

This study is an adaptive, randomized, open-label, controlled clinical trial, performed worldwide in collaboration with WHO and INSERM.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Professor Dr. Bernd Mühlbauer

Collaborators:

Dept. of Statistics and Medical Biometry, University of Bremen
INSERM (Institut national de la santé et de la recherche médicale), Paris, France
World Health Organization (WHO), R&D Blueprint, Geneva, Switzerland

Treatments:

Remdesivir